| Literature DB >> 30485720 |
Sarah-Jane Anderson1, Geoffrey P Garnett2, Joanne Enstone3, Timothy B Hallett1.
Abstract
INTRODUCTION: Setting and monitoring progress towards targets for HIV control is critical in ensuring responsive programmes. Here, we explore how to apply targets for reduction in HIV incidence to local settings and which indicators give the strongest signal of a change in incidence in the population and are therefore most important to monitor.Entities:
Keywords: HIV Infections; epidemiology; forecasting; models; population surveillance; programme evaluation; theoretical
Mesh:
Year: 2018 PMID: 30485720 PMCID: PMC6260921 DOI: 10.1002/jia2.25203
Source DB: PubMed Journal: J Int AIDS Soc ISSN: 1758-2652 Impact factor: 5.396
Minimum and maximum values of model parameters which are varied to give the “Universe of Plausible Projections”
| Minimum | Maximum | |
|---|---|---|
| Behavioural parameters | ||
| Proportion change in partner change rate in FSW (from “baseline” in 2015) | −0.5 (50% reduction in partner change rate) | 0.1 (10% increase in partner change rate) |
| Proportion change in partner change rate in low‐risk women (not FSW) (from “baseline” in 2015) | −0.2 (20% reduction in partner change rate) | 0.1 (10% increase in partner change rate) |
| Proportion change in partner change rate in heterosexual men (from “baseline” in 2015) | −0.2 (20% reduction in partner change rate) | 0.1 (10% increase in partner change rate) |
| Proportion change in partner change rate in MSM (from “baseline” in 2015) | −0.5 (50% reduction in partner change rate) | 0.1 (10% increase in partner change rate) |
| Proportion change in condom use (casual partnerships) (from “baseline” in 2015) | −0.2 (20% reduction) | 0.1 (10% increase) |
| Proportion change in condom use (low‐risk partnerships) (from “baseline” in 2015) | −0.2 (20% reduction) | 0.1 (10% increase) |
| Proportion change in condom use (commercial partnerships) (from “baseline” in 2015) | −0.5 (50% reduction) | 0.1 (10% increase) |
| Proportion change in condom use (partnerships in MSM) (from “baseline” in 2015) | −0.5 (50% reduction) | 0.1 (10% increase) |
| Programmatic parameters | ||
| Circumcision rate (an additional intervention‐ capped so that only “on” if circumcision in the population is at <80%) | 0 | 0.2 (per year) |
| PrEP coverage in FSW | 0 | 0.5 (50% coverage) |
| PrEP coverage in low‐risk women | 0 | 0.25 (25% coverage) |
| PrEP coverage in heterosexual men | 0 | 0.25 (25% coverage) |
| PrEP coverage in MSM | 0 | 0.5 (50% coverage) |
| Reduction in efficacy due to incomplete PrEP adherence | 0.6 | 0.9 |
| Treatment programme parameters | ||
| Proportion of those entering ART from low CD4 (<200) with good adherence | 0.6 | 0.95 |
| Proportion of those ART from high CD4 (>200) with good adherence entering | 0.3 | 0.9 |
| Rate of drop out from HIV programme | 0.001 (per year) | 0.04 (per year) |
| Proportion of those who drop out that can reinitiate | 0.4 | 0.7 |
| Net survival time on ART | 17 years | 40 years |
| Proportion who can drop out from the treatment programme | 0.5 | 1 |
| Proportion of FSW who receive early ART (all CD4) | 0.4 | 0.8 |
| Proportion of low‐risk women (not FSW) who receive early ART (all CD4) | 0.2 | 0.4 |
| Proportion of heterosexual men who receive early ART (all CD4) | 0.2 | 0.4 |
| Proportion of MSM who receive early ART (all CD4) | 0.4 | 0.8 |
ART, antiretroviral therapy; FSW, female sex workers; MSM, men who have sex with men; PrEP, pre‐exposure prophylaxis.
List of indicators simulated in the modela
| WHO global indicator? | |
| 1. ART programme | |
| Change in HIV prevalence (not virally suppressed) | |
| Change in HIV prevalence (not virally suppressed) in MSM | |
| Change in HIV prevalence (not virally suppressed) in men | |
| Change in HIV prevalence (not virally suppressed) in women | |
| Change in HIV prevalence (not virally suppressed) in FSW | |
| Change in proportion of the population on ART | WHO 6: percentage on ART |
| Change in number on ART | |
| Change in number on ART (MSM) | |
| Change in number on ART (men) | |
| Change in number on ART (women) | |
| Change in number on ART (FSW) | |
| Change in proportion who are eligible who are on ART (eligibility defined here based on “treatment policy in the model”) | |
| Change in proportion of those HIV positive who are on ART | |
| Change in reported ART coverage (CD4 < 200) | |
| Change in number eligible who are not on ART | |
| Change in the fraction of those initiating with CD4 category (0 to 200) | |
| Change in the fraction of those initiating with CD4 category (200 to 350) | |
| Change in the fraction of those initiating with CD4 category (350 to 500) | |
| Change in the fraction of those initiating with CD4 category (500+) | |
| Change in proportion retained and surviving after 12 months on ART | WHO 7: percentage retained and surviving on ART 12 months after initiation |
| Change in percentage of those on treatment who are virally suppressed (<12 months) | WHO 8: percentage on ART who are virally suppressed |
| Change in percentage of those on treatment who are virally suppressed (>12 months) | |
| 2. Changes in behaviour | |
| Proportionate change in partner change rate in FSW | |
| Proportionate change in partner change rate in low‐risk women | |
| Proportionate change in partner change rate in heterosexual men | |
| Proportionate change in partner change rate in MSM | |
| Overall change in the partner change rate in the population | |
| Change in condom use at last sex (casual partnerships) | |
| Change in condom use at last sex (low‐risk partnerships) | |
| Change in condom use at last sex (commercial partnerships) | WHO 3: percentage condom use in key populations |
| Change in condom use at last sex (partnerships in MSM) | WHO 3: percentage condom use in key populations |
| 3. Programmatic indicators | |
| Change in circumcision coverage | |
| Change in percentage using PrEP in priority populations | |
| Change in PrEP coverage in FSW | |
| Change in PrEP coverage in low‐risk women | |
| Change in PrEP coverage in heterosexual men | |
| Change in PrEP coverage in MSM | |
| Change in PrEP efficacy (i.e. due to changes in adherence) |
ART, antiretroviral therapy; FSW, female sex workers; MSM, men who have sex with men; PrEP, pre‐exposure prophylaxis.
Those indicators which are included in the WHO global indicator list are indicated.
Figure 1Classification of the forty‐eight modelled locations into five epidemic types
This figure describes the classification of counties according to their epidemiological characteristics for each location (horizontal axis) of the five epidemic types (groups 1 to 5 delineated with vertical white lines). The top panel shows the PAF by sub‐population (vertical axis) across locations (horizontal axis) in each epidemic group and the bottom panel shows the HIV prevalence across locations (horizontal axis) in each epidemic group. Here, groups 1 to 3 represent those epidemics with a relatively high dependency on transmission from high‐risk groups. Group 1 represents those epidemics with high PAF values in both general and high‐risk populations. Group 2 represents those epidemics with large PAF values for MSM and group 3 represents FSW‐driven epidemics. Groups 4 and 5 describe those epidemics with lower contributions from higher risk groups and a greater dependency on the general population. Group 4 represents more established epidemics and very high prevalence settings. Group 5 represents those epidemics with most transmission in the general population but with generally lower population prevalence than in group 4. FSW, female sex workers; MSM, men who have sex with men; PAF, population attributable fraction.
Figure 2Change in incidence observed by 2030 from 2015 levels for each modelled location (left panel) and nationally (Right Panel)
Each line corresponds to a different location, with the maximum and minimum value corresponding to the maximum and minimum change in incidence between 2015 and 2030 across the modelled future scenarios (the universe of plausible projections). The colour of each plotted location corresponds to the epidemic group it belongs to. Here, groups 1 to 3 represent those epidemics with a relatively high dependency on transmission from high‐risk groups. Group 1 represents those epidemics with high PAF values in both general and high‐risk populations. Group 2 represents those epidemics with large PAF values for MSM and group 3 represents FSW‐driven epidemics. Groups 4 and 5 describe those epidemics with lower contributions from higher risk groups and a greater dependency on the general population. Group 4 represents more established epidemics and very high prevalence settings. Group 5 represents those epidemics with most transmission in the general population but with generally lower population prevalence than in group 4. FSW, female sex workers; MSM, men who have sex with men; PAF, Population Attributable Fraction.
Figure 3Strength of each indicator in predicting long‐term changes in incidence for each epidemic type
Dark colours are those indicators with low adjusted R2 values (blue), light colours are those indicators with high adjusted R2 values and that perform much more strongly (yellow). Group 1 represents those epidemics with high PAF values in both general and high‐risk populations. Group 2 represents those epidemics with large PAF values for MSM and group 3 represents FSW‐driven epidemics. Groups 4 and 5 describe those epidemics with lower contributions from higher risk groups and a greater dependency on the general population. Group 4 represents more established epidemics and very high prevalence settings. Group 5 represents those epidemics with most transmission in the general population but with generally lower population prevalence than in group 4. FSW, female sex workers; PAF, Population Attributable Fraction; MSM, men who have sex with men.